派能达胶囊对慢乙肝肝硬化患者HBeAg阴转率及IL-2水平的影响  

The Effect of Painengda on the Negative Rate of HBeAg and IL-2 Level of Patients with Chronic Hepatitis B and Liver Fibrosis

作　　者：叶蕾[1] 高瑞兰[1] 余亚平[1] 

机构地区：[1]浙江中医药大学附属第一医院,浙江杭州310006

出　　处：《云南中医学院学报》2015年第4期64-66,共3页Journal of Yunnan University of Traditional Chinese Medicine

基　　金：2012年浙江省中医药科学研究基金计划项目(2012ZA041)

摘　　要：目的通过观察派能达胶囊对慢乙肝肝硬化患者HBeAg阴转率及IL-2水平的影响探讨其是否可增强抗病毒治疗疗效,为临床慢乙肝肝硬化的治疗提供帮助。方法对照组用抗病毒药(拉米夫定100mg/d+阿德福韦酯10mg/d),治疗组加用派能达胶囊(2粒/次,2次/d);派能达胶囊治疗6个月,治疗结束后所有患者继续服用抗病毒药物并随访9个月。乙肝三系每3月检测1次;治疗前及治疗结束时检测IL-2水平。结果经派能达胶囊治疗的患者治疗结束后的第6个月及第9个月,HBeAg阴转率高于对照组(P<0.05);治疗后治疗组IL-2水平高于对照组(P<0.05);治疗后治疗组IL-2水平较治疗前显著升高(P<0.05)。结论派能达胶囊可与西药联合应用于慢乙肝肝硬化患者,提高HBeAg阴转率,提高抗病毒疗效,为今后治疗慢乙肝及乙肝肝硬化提供安全有效的新方案。Objective To observe the effect of Painengda on the negative rate of HBeAg and IL-2 level of patients with Chronic Hepatitis B and Liver fibrosis, investigate whether it can improve the curative effect of anti hepatitis B virus, and supply help in treatment of patients with Chronic Hepatitis B and Liver fibrosis. Methods The selected 60 patients were randomly assigned to twoGroups （30 patients in each group）, the control group were treated by nucleoside analogues （Lamivudine 100mg and Adefovir 10mg once a day） while the treated group were treated by nucleoside analogues （the same as the control group） and Painengda, which dose was 2 pills twice a day. After 6 months, the treatment of Painengda was stopped, the treatment of nucleoside analogues going on in both of the groups and followed up for 9 months. In the study, every 3 months the detection of hepatitis B three was done; IL-2 levels were detected before and after treatmet. Results In the sixth and ninth month after the treatment of Painengda, the negative rate of HBeAg in the treated group was higher than that in the control group （P〈0. 05）; The IL-2 level was higher in the treated group than that in the control group, too（P〈0. 05）;In the treated group itself , IL-2 level was enhanced after treatment （P〈 0. 05）. Conclusion Painengda combined with western medicine can improve the negative rate of HBeAg and improve the curative effect of anti hepatitis B virus, which helps more in treatment of patients with Chronic Hepatitis B and Liver fibrosis.

关 键 词：派能达 慢性乙型病毒性肝炎 肝硬化 HBEAG IL-2 

分 类 号：R256.4[医药卫生—中医内科学]